How about the development of biomedical industry in the Pearl River Delta?

Guangdong, Hong Kong and Macao Bay area is an important area for China's biopharmaceutical industry to gather, with complete industrial foundation, leading industrial strength and outstanding industrial achievements It has key biopharmaceutical development cities such as Guangzhou and Shenzhen, and relies on the biological industry base of Guangzhou Science City, Shenzhen national biological industry base, Zhongshan Torch High-tech Industry Development Zone and other core bases The biopharmaceutical industry is located in the whole country In a pivotal position 1、 Overall, the overall strength of the region ranks the third in the main biomedical cluster areas [1], with 7 key parks and 2 component parks, ranking the third and fourth in terms of enterprise strength and innovation ability （1） Key parks have 7 key parks, accounting for 10% of the total 74 [2] key parks in China In terms of the regional distribution of the park, Guangzhou has three, Shenzhen has two, Dongguan and Zhongshan each have one See Table 1 Table 1 Distribution of nine key parks in Pearl River Delta in Dawan district has two component parks, namely, Guangzhou Science City biological industry base and Zhongshan Torch High Technology Industry Development Zone, accounting for 10% of the total 20 [3] component parks in China （2） The number of high-tech enterprises, top 100 pharmaceutical enterprises and listed enterprises in the enterprises strength area accounts for 9.1%, 13.0%, 4.5% and 12.3% of the 74 key parks in China respectively See Figure 1 Figure 1 data source of the proportion of enterprises indicators of nine cities in Pearl River Delta of Dawan District in 74 parks in China: compared with other major biopharmaceutical clusters in China, all of the above indicators rank the third in China See Table 2 Table 2 comparative data sources of the second level indicators of the strength of enterprises in different regions: the number of applications for invention patents of innovation ability, the number of clinical trials of drugs, the total number of CDE drugs accepted and the number of drugs on the market, and the number of class II and class III medical devices and high-level talents on the market respectively account for 12.9%, 5.2%, 4.7% and 3.6% of the 74 key parks in China 9.9% and 1.7% See Figure 2 Figure 2 the proportion of innovation indicators of nine cities in the Pearl River Delta in China 's 74 parks data source: compared with other major concentration areas of biological medicine in China, two indicators are in the third place, and four indicators are in the fourth place See Table 3 Table 3 comparative data sources of the second level index ranking of enterprise capacity in different regions: Huoshi creation II Case analysis of the park (I) Guangzhou Science City biological industry base, Guangzhou Science City biological industry base, ranked 12th in enterprise strength and 36th in innovation ability; 5 indexes entered the top 10, and 6 indexes ranked 11th-42nd See Figure 3 Figure 3 ranking data source of Guangzhou Science City biological industry base in 74 parks in China: flint creation 1 Industrial subject and strength: 12th in China, and the number of listed enterprises in the top three Guangzhou Science City biological industry base unit [4] ranked 11th in the total number of enterprises; The number of unit high-tech enterprises ranked sixth; the number of listed enterprises ranked third; the number of top 100 pharmaceutical enterprises and unicorn enterprises ranked 18th and 6th respectively 2 Innovative products and capabilities: ranked 36th in China, and the number of drugs on the market is small From the perspective of innovation layout, Guangzhou Science City biological industry base ranks 8th in terms of the number of domestic invention patent applications, 10th in terms of the total number of drug clinical trials, and 23rd in terms of the total number of CDE drug acceptance From the perspective of products on the market, the number of medical devices in the second and third categories on the market ranked 11th, and the number of drugs on the market ranked 42nd In terms of innovative talents, the number of high-end talents per unit ranks 11th 3 Facing the future: give full play to the advantages of international hub, build a scientific and technological innovation and entrepreneurship center, Guangzhou Science City biological industry base, focus on biopharmaceutical, high-end medical equipment and biomedical materials, testing and in vitro diagnostic products, stem cells and regenerative medicine industry, give full play to the international hub magnetic field effect, gather high-end global innovation resources, and build a first-class life science and Biology Pharmaceutical industry ecosystem, to create a global influence of biomedical and health industry highland （2） Zhongshan Torch High tech Industrial Development Zone ranks 19th in enterprise strength and 18th in innovation ability; 2 indexes are in the top 10 and 9 indexes are in the 12th-39th See Figure 4 Figure 4 ranking data source of Torch Development Zone in 74 parks in China: flint creation 1 Industrial subject and strength: the 19th in China, with medium enterprise strength The Torch Development Zone ranks 29th in the total number of unit enterprises, 21st in the number of unit high-tech enterprises, 5th in the number of top 100 pharmaceutical enterprises, 24th in the number of listed enterprises and 6th in the number of Unicorn enterprises 2 Innovative products and capabilities: the 18th place in China, R & D capability to be strengthened From the perspective of innovation layout, Torch Development Zone ranks 30th in terms of the number of domestic invention patent applications, 23rd in terms of the total number of drug clinical trials, and 34th in terms of the total number of CDE drug acceptance From the perspective of listed products, the number of Listed Medical Devices ranked 29th, and the number of listed drugs ranked 12th In terms of innovative talents, the number of high-level talents per unit ranks 39th 3 Facing the future: taking advantage of Guangdong Hong Kong Macao Bay area to build a strong industrial manufacturing area Relying on the National Health Science and technology industrial base, South China Modern Chinese medicine city and Sino German (Zhongshan) biomedical industrial park, the Torch Development Zone is built into a competitive biomedical industry manufacturing area in China, focusing on the biopharmaceutical industry, medical equipment, medical information, health service industry and other industrial clusters, with the help of the geographical advantages of Guangdong, Hong Kong and Macao Dawan district 3、 Outlook Guangdong, Hong Kong and Macao Dawan district is an important area for China's biopharmaceutical industry to gather As the leading cities of the regional biopharmaceutical industry, Guangzhou and Shenzhen have good industrial foundation and complete industrial chain Dual core drive drives the rapid improvement of the biopharmaceutical industry in Dawan District, ranking the third largest biopharmaceutical industry gathering area in China The strength of the main biopharmaceutical industry parks is outstanding, increasing Speed is always in the forefront of China What's striking is that Shenzhen has made remarkable achievements in technological innovation, industrial transformation and upgrading, relying on the basis of biological information industry, the carrier of national industrial parks, and the growing biomedical industry cluster Shenzhen's biomedical industry has outstanding characteristics, its core hub position attracts talents, technology, capital and other resources, and the industry continues to move towards a high-speed and high-quality development path In the future, Dawan district also needs to make efforts to improve the scale of small and medium-sized enterprises and innovation service capacity, and promote the development of biomedical industry to high-end, digital and intelligent by building a new path of Bt + it, building an innovation platform and other measures [1] Major biomedical agglomeration areas in China: Yangtze River Delta, Bohai rim, Dawan Pearl River Delta, Jiucheng and Chengdu Chongqing [2] 74 Park sources: according to the distribution of bases in the biomedical field of the national development and Reform Commission, the Ministry of industry and information technology, the Ministry of science and technology, and the biomedical industry cluster issued by China Biotechnology Center and the Ministry of Commerce, there are 74 parks recommended twice or more, including 23 National biomedical industry bases of the national development and Reform Commission, which are typical and representative 。 [3] 20 component Park sources: from 74 key biomedical industry parks in China, the comprehensive calculation is based on two first-class indicators of enterprise strength and innovation capacity, and 11 second-class indicators [4] Due to the large difference in the area of the park, eight secondary indicators are ranked as a unit (except the number of Unicorn enterprises, the number of top 100 pharmaceutical enterprises, and the number of listed enterprises).